Breadcrumb

[A19-94] Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-11-15 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 361 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A20-33] Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2020-02-17 Extract of dossier assessment 361 kBPDFdownload file
2020-02-17 Dossier assessment (German version) 544 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V [PDF, 361 kB]



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close